Arry-403 second quarter 2010
Arry-520 December 2009 advanced leukemia
Arry-380 (ERBB2 inhibitor) second week of Dec. 2009
Arry-543 erbb family inhibitor, late Nov. 2009 (combination with other drugs) cancer

HCV protease inhibitor.
Intermune and Roche announced impressive results from HCV trial. The trial used the drug (RG7227) co-developed with ARRY. They also started two phase II trials with it. Evidently, Roche is very high on this compound. Roche recently declined to exercise options to obtain similar drugs from IDIX. In the future, this compound could be a revenue generator for ARRY. It is far from a home run, but it could sustain ARRY for other development.

Overall, ARRY has to obtain good clinical data from its own trials. Some are coming very soon.

Day 13 Viral Kinetic Results: Higher-Dose Twice-Daily Regimens

HCV RNA HCV RNA
Regimen <LLOQ(1) <LLOD(2)
(RG7128 / Patient (<43 IU/mL) (<15 IU/mL)
RG7227 mg) N Population N (%) N (%)
--------- - ------------- ---- ----
1000/600 BID 8 TF-Non-Null 4/8 (50%) 1/8 (13%)
-------------- - ----------- -------------- -------------------
1000/900 BID 8 TF-Null 4/8 (50%) 2/8 (25%)
-------------- - ------- -------------- -------------------
1000/900 BID 8 Naive 7/8 (88%) 5/8 (63%)
-------------- - ----- -------------- -------------------

(1) LLOQ = lower limit of quantification by Roche TaqMan Assay
(<43 IU/mL)
(2) LLOD = lower limit of detection by Roche TaqMan Assay (<15 IU/mL)